Cardiac anticoagulation therapy plays a pivotal role in the nuanced landscape of cardiovascular care. Tailored to individuals at risk of blood clot formation, this specialized therapy is a key element in preventing potential complications such as strokes or heart attacks. Commonly prescribed for conditions like atrial fibrillation, deep vein thrombosis, or those with mechanical heart valves, cardiac anticoagulation therapy involves the use of medications like warfarin or direct oral anticoagulants. These medications exert their effect by disrupting the blood clotting process, promoting a smoother flow of blood through the heart and vessels. The meticulous administration of cardiac anticoagulation therapy demands vigilant monitoring and personalized dosing to strike an optimal balance between preventing clots and minimizing the risk of bleeding complications. As research in the medical field progresses, ongoing refinements in cardiac anticoagulation therapies hold the promise of enhanced efficacy, reduced side effects, and improved overall outcomes for individuals managing cardiovascular conditions.
Title : Investigating the long-term follow up of atrial septal device closures in wales and england: A comparative analysis with major adverse cardiovascular Events (MACE)
Meera Gopinath, Cardiff University Medical school, United Kingdom
Title : An adult case of polysplenia syndrome associated with sinus node dysfunction
Apoorva Tripathi, Oxford University Hospitals, United Kingdom
Title : A unique cell-driven phenomenon in the heart and the promising future of the innovative translational tools to manage cardiac self-renewal and regeneration
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Yasser’s criterion of inferior ST-segment discrepancy deviations in AF with aberrancy and Sgarbosa criteria - a new cardiovascular discovery and management - a case report
Yasser Mohammed Hassanain Elsayed, Egyptian Ministry of Health, Egypt